Advert for Healthcare Professionals Only
I am a patient (Please go to our patient website)
- All Topics
- Allergy and Clinical Immunology
- Anesthesiology
- Angiology
- Cardiology
- Central Nervous System
- Clinical Laboratory
- Complementary and Alternative Medicine
- Critical Care/Intensive Care
- Dermatology
- Diabetes and Endocrinology
- Ear, Nose and Throat
- Emergency Medicine
- Eye Health and Disorders
- Family Medicine
- Gastroenterology
- Gerontology/Geriatrics
- Haematology
- Hepatology
- HIV/AIDS
- Immunology
- Infectious Diseases
- Internal Medicine
- Kidney and Urological Diseases
- Medical Genetics
- Men's Health, Andrology and Urology
- Musculoskeletal Disorders
- Neonatal/Perinatal Medicine
- Neurological Disorders
- Nutrition and Dietetics
- Oncology
- Orthopaedics
- Paediatrics
- Pain Management
- Palliative Medicine
- Plastic Surgery and Aesthetic Medicine
- Podiatry
- Preventive Medicine
- Psychiatry/Mental Health
- Radiology
- Respiratory
- Rheumatology
- Sexual Health
- Sleep Medicine
- Sports Medicine
- Surgery (General)
- Transplantation
- Tropical Medicine
- Vaccines
- Women's Health and Obs/Gyn
- ADHD
- Alzheimer's Disease
- Arthritis
- Atopic Dermatitis
- Cholesterol
- Chronic Myeloid Leukemia
- COPD
- Cystic Fibrosis
- Diabetes
- Gastrointestinal Stromal Tumours
- Hepatitis
- Hypertension
- Insomnia
- Lysosomal Storage Disorders
- Men's Health
- Multiple Sclerosis
- Niemann-Pick type C
- NSCLC
- Opioids and Pain
- Parkinson's Disease
- Post-Myocardial Infarction
- Prostate Cancer
- Renal Anaemia
- Renal Cell Carcinoma
- Soft Tissue Sarcoma
- Third Party Website - Asthma and COPD
- CAPOZIDE TABLETS
- SURMONTIL 10MG AND 25MG TABLETS
- NAPRATEC OP
- COBALIN-H INJECTION
- CARBEX
- CALCIUM RESONIUM 99.934% W/W POWDER FOR ORAL/RECTAL SUSPENSION
- HYPURIN BOVINE ISOPHANE
- HYPURIN BOVINE LENTE
- HYPURIN PORCINE 30/70 MIX CARTRIDGES
- HYPURIN BOVINE ISOPHANE VIALS
- DUKORAL ORAL CHOLERA VACCINE
- OXYNORM LIQUID 5 MG/5 ML ORAL SOLUTION
- DORZOLAMIDE/TIMOLOL EYE DROPS
- FENOFIBRATE 267MG CAPSULES
- TRACRIUM INJECTION
- EXOCIN
- FRAGMIN - TREATMENT OF VTE
- FLUDARABINE PHOSPHATE 50 MG POWDER FOR SOLUTION FOR INJECTION OR INFUSION
- GABITRIL FILM-COATED TABLETS (5 , 10, 15 MG)
- PROTOPIC 0.03% OINTMENT
- XISMOX 60 XL PROLONGED RELEASE TABLETS
- PALLADONE SR CAPSULES
- ZINERYT
- PURI-NETHOL 50 MG TABLETS
- DAKTACORT OINTMENT
- MYLERAN 2 MG FILM-COATED TABLETS
- NEOTIGASON 10MG CAPSULES
- LEUKERAN TABLETS 2 MG
- LANVIS TABLETS 40 MG
- PROVIGIL 100 MG TABLETS, PROVIGIL 200 MG TABLETS
- ADHD
- Alzheimers
- Anxiety Disorders
- Arthritis
- Asthma
- Avonex
- Breast Cancer
- Cervical Cancer
- Cholesterol
- Colorectal Cancer
- Copaxone
- Depression
- Diabetes
- Erectile Dysfunction
- Extavia
- Hypertension
- Insomnia
- Men's Health
- Meningitis
- Migraine
- Pain Management
- Parkinson's
- Pharma News
- Post-MI
- Pregnancy
- Prostate
- Rebif
- Renal anaemia
- Renal Cell Carcinoma
- Thrombosis
- Thromboembolism
- Tysabri
Advert for Healthcare Professionals Only
Latest Drugs
Oncology Drug Data - A-Z (English)
Drug Class Description
Cytotoxic antibiotics.Generic Name
IdarubicinDrug Description
Zavedos Injection: powder in vials. Zavedos Capsules: 5 mg red capsules; 10 mg red/white capsules; 25 mg white capsules.Presentation
Zavedos Injection: Idarubicin hydrochloride 5 mg , 10 mg . Zavedos Capsules: Idarubicin hydrochloride 5mg , 10mg , 25mg .Indications
Injection: Acute non-lymphocytic leukaemia (ANLL) in adults for remission induction in untreated patients or for remission induction in relapsed or refractory patients. Acute lymphocytic leukaemia (ALL) as second line therapy in adults and children.
Capsules: Whenever intravenous idarubicin cannot be employed for untreated, relapsed or refractory ANLL. May also be used as a single agent to treat advanced breast cancer after failure of frontline chemotherapy not including anthracyclines. Capsules and injection may be used in combination chemotherapy regimens involving other cytotoxic agents.
Manufacturer
Pharmacia & UpjohnDrug Availability
(POM)Updated
16 June 2009Advert for Healthcare Professionals Only
Related News
Genentech files vismodegib at FDA for Basal Cell Carcinoma Oncology Page
Genentech/Roche has submitted a new drug application to the FDA for vismodegib as a treatment for patients with advanced, inoperable basal cell carcinoma . The new oral drug is designed to selectively inhibit signaling in the Hedgehog pathway, which is implicated in more than 90% of basal cell carcinoma cases, the most common type of skin cancer, which is generally curable by surgery.
Provenge sales for Prostate Cancer disappoint Dendreon and lead to staff reduction Oncology Page
Dendreon will reduce its workforce by 500 employees( about one-quarter of its work force)as sales of its prostate cancer immunotherapy, Provenge(sipuleucel-T) have disappointed and are well short of its projections. The largest proposed job cuts are in manufacturing but the company is looking for a partner in Europe as its moves toward filing for approval of Provenge there by the end of 2011.
New study of Cervarix shows two doses are adequate against HPV types 16 and 18 Oncology Page
A new study of Cervarix (papillomarvirus vaccine) from Glaxo Smith Kline, finds that to protect women from HPV types 16 and 18, which account for 70% of cervical cancer cases, two doses of the vaccine are as effective as the standard three doses over a four-year period. The study, reported in The Journal of the National Cancer Institute, uses data from a community-based Cervarix trial in Costa Rica. Women were randomly selected to receive either Cervarix or a Hepatitis A vaccine control. Researchers had intended to give all 7,466 subjects the full course of three vaccines. However, approximately 20% only completed two doses of HPV or control vaccine. Those who had two doses were found to have the same strong protection as the ones who received three, after four years of follow up. The researchers observe that a single dose might also provide a high level of protection. J Natl Cancer Inst (2011) doi:10.1093/jnci/djr319
